Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Legend Biotech Corporation filings document foreign private issuer current reports, operating updates, governance actions, registration statements, and equity-plan disclosures for a cell therapy biopharmaceutical company. Its Form 6-K reports cover CARVYKTI® preliminary sales information received through the Janssen collaboration, quarterly and annual financial-result releases, corporate presentations, and clinical updates involving the CARTITUDE program and LUCAR-G39D.
The company’s regulatory disclosures also record board appointments and resignations, audit committee leadership, director compensation under restricted share unit plans, and related-party matters involving GenScript. Incorporated Form F-3 and Form S-8 references connect current reports with securities registration and incentive-plan filings, while risk language addresses forward-looking statements, product development, collaboration economics, and commercialization of CAR-T therapies.
Legend Biotech Corporation disclosed that Chief Executive Officer Ying Huang resigned from his roles as CEO and board member, effective July 24, 2026. He is expected to continue as an advisor through August to support a smooth transition, and the resignation is stated not to result from any disagreement regarding operations, policies, practices, financial statements, or internal controls over financial reporting.
On July 23, 2026, the board appointed Alan Bash as Interim Chief Executive Officer and interim principal executive officer, effective as of the same effective date. Bash has led CARVYKTI as President since October 2024 and previously held senior roles at ZielBio, Checkmate Pharmaceuticals, and Bristol Myers Squibb. The company notes there is no arrangement or understanding under which he was selected, no related party transactions with him requiring disclosure, and no family relationships with current directors or executive officers.
Legend Biotech reports preliminary commercial performance for CARVYKTI® under its collaboration with Janssen. Based on data provided by Janssen, CARVYKTI® generated approximately $657 million in net trade sales for the quarter ended June 30, 2026. This figure has not been independently verified by Legend Biotech, and the final amount of revenue and gross profit to be recognized in Legend Biotech’s financial statements will be determined after management completes the preparation of its results for the period. Legend Biotech’s independent registered public accountants have not audited, reviewed or performed procedures on this sales data.
The company includes forward-looking statements about expectations for CARVYKTI® net trade sales and resulting gross profit, noting that actual results may differ materially due to factors such as drug development risks, unexpected clinical or regulatory outcomes, partner actions, intellectual property challenges including U.S. litigation, competition, and pricing and political pressures. These risks are further described in the Risk Factors section of Legend Biotech’s Annual Report on Form 20-F filed on March 10, 2026. This report is also incorporated by reference into Legend Biotech’s existing Form F-3 and Form S-8 registration statements, to the extent not superseded by later filings.
Legend Biotech Corp director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction. The sale took place at $14.80 per ordinary share, equivalent to $29.60 per American Depositary Share, with each ADS representing two ordinary shares. After this trade, he directly holds 48,604 Ordinary Shares, indicating he retains a substantial ongoing equity position in the company.
Legend Biotech Corp director and CEO Ying Huang reported a charitable stock gift. On this Form 4, Huang made a bona fide gift transfer of 3,382 Ordinary Shares of Legend Biotech Corp to a charitable organization, receiving no cash consideration.
After the gift, Huang directly owns 238,490 Ordinary Shares. The company notes that its Ordinary Shares may be represented by American Depositary Shares, with each ADS representing two Ordinary Shares.
The filing is a Form 144 notice regarding proposed sales of American Depositary Shares. The excerpt lists a broker (Fidelity Brokerage Services LLC) and a proposed sale quantity of 3,000 ADS with an associated figure of $88,800.00. The record also shows multiple prior restricted stock vesting events totaling 3,000 ADS on specific vesting dates.
Legend Biotech Corp Chief Executive Officer Ying Huang reported a disposition of ordinary shares tied to equity compensation taxes. On June 25, 2026, 5,566 ordinary shares were sold at a weighted average price of $14.78 per share, based on converted ADS prices.
According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units, making this a compensation-related, non-discretionary event rather than a typical open-market sale. Following the transaction, Huang directly holds 241,872 ordinary shares of Legend Biotech.
LEGN filed a Form 144 proposing the sale of 2,783 American Depositary Shares. The filing lists the shares as from a Restricted Stock Vesting event with a record date of 06/22/2026. The notice references $79,016.88 on the same line and lists execution via Fidelity Brokerage Services LLC on 06/26/2026.
The filing also discloses a prior disposition by Ying Huang of 4,968 American Depositary Shares on 03/26/2026 with a figure of $87,149.15 shown. The securities are listed for trading on NASDAQ.
Legend Biotech Corporation launched an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares, at $29.35 per ADS. All ADSs are being sold by the company under its effective shelf registration.
The company expects net proceeds of approximately $211.6 million after underwriting discounts and expenses, assuming the underwriters do not exercise their option. The underwriters also have a 30-day option to buy up to 1,155,000 additional ADSs. The offering is expected to close on June 23, 2026, subject to customary conditions.
Legend Biotech Corporation is offering 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares, at an initial public offering price of $29.35 per ADS. The offering represents 15,400,000 ordinary shares and includes an underwriters’ option to purchase up to 1,155,000 additional ADSs. Net proceeds are estimated at approximately $211.6M before expenses (or approximately $243.5M if the option is exercised in full).
The company intends to use proceeds to fund pipeline development, including LB2501, for working capital and general corporate purposes. Combined with existing cash and cash equivalents as of March 31, 2026, Legend expects funding through the fourth quarter of 2027 under its current operating plan.
Legend Biotech Corporation is offering $225,000,000 of American Depositary Shares (ADSs) in a primary offering, with each ADS representing two ordinary shares. The ADSs trade on Nasdaq under the symbol LEGN; the prospectus cites 371,479,583 ordinary shares outstanding as of March 31, 2026 and a historical net tangible book value of $966.0 million (equivalent to $2.61 per ordinary share or $5.22 per ADS). The prospectus identifies use of proceeds for pipeline development including LB2501, working capital and general corporate purposes and discloses typical underwriting arrangements, lock-up restrictions and regulatory risk factors for PRC-based issuers.